Targeting Siglec‐10+ macrophages in GC through Siglec‐10 blocking enhanced anti‐tumour immunity and synergistically improved response to anti‐PD‐1 immunotherapy in ex vivo tumour models. This evidence concerns the gene SIGLEC10 and neoplasm.